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Abstract 
The main aim of radiotherapy is to deliver a dose of radiation that is high enough to destroy 
the tumour cells while at the same time minimising the damage to normal healthy tissues. 
Clinically, this has been achieved by assigning a prescription dose to the tumour volume and a 
set of dose constraints on critical structures. Once an optimal treatment plan has been 
achieved the dosimetry is assessed using the physical parameters of dose and volume. There 
has been an interest in using radiobiological parameters to evaluate and predict the outcome 
of a treatment plan in terms of both a tumour control probability (TCP) and a normal tissue 
complication probability (NTCP). In this study, simple radiobiological models that are 
available in a commercial treatment planning system were used to compare three dimensional 
conformal radiotherapy treatments (3D-CRT) and intensity modulated radiotherapy (IMRT) 
treatments of the prostate. Initially both 3D-CRT and IMRT were planned for 2 Gy/fraction to 
a total dose of 60 Gy to the prostate. The sensitivity of the TCP and the NTCP to both 
conventional dose escalation and hypo-fractionation was investigated. The biological 
responses were calculated using the Källman S-model. The complication free tumour control 
probability (P+) is generated from the combined NTCP and TCP response values. It has been 
suggested that the α/β ratio for prostate carcinoma cells may be lower than for most other 
tumour cell types. The effect of this on the modelled biological response for the different 
fractionation schedules was also investigated.    
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Introduction 
Prostate cancer is potentially curable if detected and treated in the early stages. There are 
several treatment options available for prostate cancer
1
. These treatment options vary 
according to the stage of the cancer and other medical conditions. Radiotherapy and surgery 
are the two main options used to eliminate the primary tumour
2
. Radiotherapy is one of the 
most effective methods for cancer treatment. It is currently in the process of rapid change. 
This movement has mainly been driven by rapid achievements in computer technology which 
led to the development of new treatment planning and delivery systems
3
. 3D-Conformal 
Radiation Therapy (3D-CRT) and Intensity Modulated Radiation Therapy (IMRT) have being 
used for both the palliative and curative treatments of cancer. The main goal of curative 
radiation therapy is to deliver a dose of radiation high enough to control the tumour while at 
the same time minimizing the radiation dose to the surrounding normal tissues. In many cases 
there is clinical evidence that increasing the tumour dose results in improved tumour control. 
This is particularly the case for prostate cancer
4, 5
  The major challenges in achieving this goal 
are the uncertainties of tumour volume delineation, minimising the effects of patient set-up 
errors and the limitations of the dose delivery system
6
. This limits the tumour dose that can be 
safely prescribed and delivered to the patient.  
 Currently, the treatment planning process is defined and evaluated only in terms of 
physical dose and physical volume. Radiobiological models attempt to describe the dose 
response of tumour and normal tissues on irradiation and also the dependence on the 
fractionation schedule. These mathematical models can be used to calculate the tumour 
control probability (TCP) and normal tissue complication probability (NTCP)
7-11
 for a given 
dose distribution. Ultimately, it would be desirable to use radiobiological models directly in 
the treatment planning optimisation process
12
. 
 The ratio α/β is a measure of a tissue’s sensitivity to fractionation, that is, the size of 
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dose given in each treatment
13
. There is an increasing body of evidence that prostate cancer 
cells behave as a late reacting tissue and that therefore the α/β value for prostate cancer cells 
could have a value as low as 1 to as high as 5
14-20
. This is in sharp contrast to the accepted 
value of 10 for most tumours. The rectum and bladder have a α/β value of 3 or 4 so if the α/β 
value for prostate cancer is indeed lower than this then it suggests that the tumour cells would 
be more sensitive to changes in the dose per fraction than the normal tissue cells and that this 
could be exploited through hypo-fractionation
21
. Clinical experience would appear to support 
this hypothesis however the relative failure of small radiation doses per fraction (< 2 
Gy/fraction) in controlling prostate cancer might be complicated further by hypoxia
22
. 
 In this study we investigate the hypothesis that IMRT can improve the clinical 
outcome for prostate radiotherapy using radiobiological models that are available in the 
Pinnacle (Philips Medical Systems) treatment planning system. The work also investigates the 
use of these radiobiological models to evaluate some of the dose escalation schedules, both 
conventional and hypo-fractionation that have been used in the radiotherapy treatment of 
prostate cancer patients. Finally, the rationale for hypo-fractionation in the treatment of 
prostate cancer is investigated by varying the α/β parameter for the prostate in the 
radiobiological models. 
 
Theory 
Advanced treatment optimization is possible using quantitative radiobiological dose response 
models
23
. Radiobiological models can quantify the response of heterogeneous tumours and 
organized normal tissues to non-uniform dose delivery. These responses can be used to find 
the right balance between cure and complications either including them directly in the 
optimization or by using them as an evaluation tool for the clinical outcome of a treatment.  
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With such models it is possible to find the intensity-modulated dose delivery that maximizes 
the complication-free cure and at the same time minimizes the risk of severe normal tissue 
side effects. The predictive power of the models is assessed through analysis of complications 
or control data before they can be considered reliable for clinical treatment planning. 
However, limited validation of these models has been performed using clinical data
20
. 
 Although there are several sophisticated models for TCP
24-26
 and NTCP
27
 that have 
been published, the radiotherapy treatment planning software Pinnacle v7.6c has been used to 
calculate the biological responses in this study for simplicity. The responses are calculated in 
Pinnacle using the Kallman S-model
28, 29
. 
 
TCP calculations 
 TCP is the probability that the tumour is completely eradicated. A radiation therapy 
plan represents a volumetric distribution of radiation dose. The TCP value for a given tumour 
volume is calculated in Pinnacle using equation  
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β is generated using equation  
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where D50 is the dose level to achieve a 50 % probability of tumour control.   
The composite value for all TCP responses is calculated using equation  
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where PB is the overall probability for benefit of the treatment by destroying all j tumours.  
 
 NTCP calculations 
 The NTCP value for a given organ is calculated using equation  
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Where, jIP  is the probability of causing normal tissue complication for organ j. 
 js  is the relative seriality of the organ j. 
 jiP  is calculated using equation (1) 
 jV  is the index set for the voxels covered by organ j. 
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where PI is the overall probability of injury to normal tissue.  
 
Complication free tumour control probability (P+) calculations 
 P+, the composite response value is generated from the combined NTCP and TCP 
response value
30
. The P+ value is calculated using equation  
IB PPP −=+                                                         (8) 
where,  PB and PI are the composite values for all TCP and NTCP given by equations (4) and 
(7)  respectively. 
 
Methods 
A prostate patient was planned using two different 3D-CRT techniques and an IMRT 
technique. The different plans were evaluated using radiobiological models that are available 
in the Pinnacle Planning system. The visible tumour, critical structures and other relevant 
landmarks were outlined slice-by-slice on the patient CT dataset. The prostate and the 
surrounding organs at risk (rectum, bladder, left and right femur heads) were outlined 
according to International Commission on Radiation Units and Measurements (ICRU) 
Reports 50 and 62
31, 32
. The volumes of these organs are shown in figure 1. For all plans in 
this study the same volumes were used. 
 
Position for figure 1. 
 
 To simplify the IMRT optimization process the beam angles are fixed. Beam angle 
selection is important however and may have an impact on the final optimized IMRT plan. 
Five photon beams were used for the IMRT plans (36
o
, 100
o
, 180
o
, 260
o
 and 324
o
). For the 
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3D-CRT plans, two different sets of beam angles were designed. Four photon beams were 
used in one plan (0
o
, 90
o
, 180
o
 and 270
o
) and in the second plan five photon beams (0
o
, 90
o
, 
120
o
, 240
o
 and 270
o
) were used.  
 The effect of different dose escalation strategies was investigated and assessed for the 
three different treatment plans using the Pinnacle radiobiological evaluation module. The 
parameters used in the radiobiological models for calculation of TCP and NTCP are listed in 
table 1. Conventional dose escalation where the dose/fraction was fixed at 2 Gy and the 
number of fractions increased was investigated. The dose, number of fractions, and the dose 
per fraction investigated for the three different treatment plans are listed in table 2. The effect 
of fixing or reducing the number of fractions and increasing the dose per fraction was also 
investigated using some published hypo-fractionation schedules for prostate patients. These 
are listed in table 3. The sensitivity of the TCP to variations in α/β over the range of 1−10 was 
investigated for the different fractionation schedules and the three planning techniques.  
Position for Table 1 
Position for Table 2 
Position for Table 3 
Results and Discussion 
Sensitivity of the radiobiological evaluation to the fractionation schedule 
TCP 
 Figure 2 shows the TCPs as a function of prescription dose planned in 30 fractions (I) 
and in 2 Gy per fraction (II) for α/β = 1, 1.5, 2, 2.5, 3, 4, 5 and 10 in three treatment plans. 
The results are shown for two conformal plans and one IMRT plan. 
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POSITION FOR FIGURE 2 
 
 In all cases, the TCPs obtained for the fixed dose/fraction are smaller by about 1 % 
than those for increased dose/fractions. Despite the difference due to dose/fraction in all cases 
IMRT gives the highest TCPs. The difference due to dose/fraction increased as prescription 
dose increased between 62 and 66 Gy. This difference gradually decreases when the 
prescription dose increases as TCPs tend to 100 %. TCPs are not so sensitive to α/β values 
when the dose/fraction is fixed compared to when when the dose/fraction is changed. If α/β is 
in fact lower than previously accepted, then changing the fraction size has an effect on the 
calculated TCP. If α/β is high then total prescription dose is the important parameter, not 
dose/fraction.  
 NTCP 
 The treatment plans are evaluated for normal tissue complications by calculating their 
corresponding NTCPs. A lower NTCP means a higher probability of normal tissue sparing. 
NTCPs were calculated for the rectum, bladder and femoral heads for the three different 
treatment plans and for the two different fractionation schedules listed in table 2. These NTCP 
values are compared in Figure 3 for investigating the effects of the dose/fraction on NTCP. 
POSITION FOR FIGURE 3 
 Figure 3 shows the NTCPs calculated for the prescription dose planned in 30 fractions, 
and the NTCPs calculated for the prescription dose planned in 2 Gy per fraction for each of 
the three treatment plans.  
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 NTCPs for the rectum are plotted in the top left panel of figure 3. It can be seen that 
the NTCPs are higher for a fixed 30 fractions than when the dose is planned for a fixed 2 Gy 
dose/fraction. So for dose escalation, higher dose/fraction increases complications. IMRT 
plans show the minimum NTCPs in both fractionation schedules. The NTCPs for bladder and 
femoral heads were calculated for both fractionation schedules and are shown in figure 3. 
 Figure 3 shows the composite NTCPs for the three treatment plans and for the dose 
planned using the different fractionation schedules. Higher dose/fraction is seen to increase 
the probability of normal tissue complications. IMRT is shown to reduce the normal tissue 
complications compared to the 3D-CRT plans.  
 
Complication free tumour control probability (P+) 
 The aim of a radiotherapy treatment is to not only have a high tumour control 
probability, but also to have low normal tissue complications probability. This can be 
evaluated in simple terms through use of the P+ described in equation (14). 
 
POSITION FOR FIGURE 4 
 
The dose/fraction is shown to have a significant effect on P+. Since high dose/fraction 
increases the NTCP more than the increase in TCP, a lower P+ is observed. The results for 
two different schedules of dose/fraction for the same prescription dose are shown in figure 4. 
The P+ for different plans is also shown. At lower doses, the dose/fraction difference is very 
small, so the differences of P+ are also small at that dose range. But for high prescription 
dose, the dose/fraction difference is large, 0.33 Gy for the case of 70 Gy, which cause a large 
NTCP. As a result P+ decreases. IMRT treatment plans show the highest P+ for all cases. The 
plots all show a maximum at around 64-66 Gy with higher doses resulting a reduction in the 
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uncomplicated control P+. The fall off in P+ is more significant for the fractionation 
schedules where the dose/fraction is increased compared to the conventional dose escalation 
with increasing number of fractions. These are calculations for single phase treatments. Most 
dose escalation trials for prostate cancer are two phases with phase one being a treatment of 
the whole PTV to around 64 Gy and phase two involving a boost dose to a reduced PTV. The 
results here validate this schedule for dose escalation; increasing the dose beyond 64-66 Gy to 
the whole PTV is seen to result in a reduction in P+ due to an increase in the NTCP. 
 
Sensitivity of the radiobiological evaluation to the α/β parameter 
 Sensitivity of the TCP and P+ to the different values of α/β ratio were investigated for 
various prescription doses planned to be delivered in either a fixed number of fractions (I) or 
in a fixed dose per fraction (II).  
  
TCP as a function of α/β 
 TCPs as a function of α/β are shown in figure 5. These were obtained for different 
prescription doses planned as either fixed number of 30 fractions and increasing the 
dose/fraction (I) or as a fixed 2 Gy/fraction and increasing the number of fractions (II). This 
was performed for each of the 3 different treatment plans. 
 
POSITION OF FIGURE 5 
 
 For all of the cases, lower α/β values give the higher tumour control probabilities 
when prescription doses are planned in 30 fractions. In those cases, the dose/fraction 
increased with prescription dose.  TCPs are not significantly sensitive to the α/β values when 
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prescription dose are planned in 2 Gy/fraction. This agrees with previous work that if indeed 
the α/β is lower than previously thought then increasing the dose/fraction would be 
radiobiologically advantageous
20
. It confirms that if α/β is really lower than expected, better 
tumour control should be achieved by fewer fractions but a larger dose/fraction
14, 16, 33
.  To 
test this further four different published hypo-fractionation trials (listed in table 3) for prostate 
cancer were investigated. Figure 6 shows the calculated (a) TCP and (b) P+ values for the 
conventional fractionation and published hypo-fractionated IMRT schedules as a function of 
the biologically equivalent 2 Gy/fraction dose. This shows that significantly higher TCP and 
uncomplicated control, P+ can be expected for only two of  the hypo-fractionation schedules, 
60 Gy (20 x 3 Gy) and 70 Gy (28 x 2.5 Gy) if the α/β closer to the previously assumed value 
of around 10. The two hypo-fraction schedules 50 Gy (16 x 3.125 Gy) and 55 Gy (20 x 2.75 
Gy) rely on α/β being lower than 10 to obtain the required gains in TCP and P+. The results 
of P+ in figure 6 compared to those in figure 4 show that if the dose / fraction are increased 
the number of fractions should also be decreased to preferentially spare the organs at risk by 
minimising the NTCP.  
 
  POSITION OF FIGURE 6 
 
The models used in the Pinnacle treatment planning system are relatively simplistic. They 
take no account of cell repopulation effects between treatment fractions and also cell 
oxygenation levels that may vary spatially and temporally within a tumour. Hypoxic cells are 
known to be more radio-resistant than oxic cells
22
. The models used in this study do not 
account for variations in dose rate; IMRT treatment times can be significantly longer than for 
a 3D conformal treatment
34
 and this has shown to affect the tumour dose-response. Also due 
to the method of delivery the dose rate can vary spatially across the tumour volume
35
.  
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Further, the radiobiological parameters used in the models to characterise the dose response 
curves, the D50, γ, seriality and α/β are subject to significant uncertainty. This limits the use of 
the simple models in calculating an absolute measure of tumour control probability and 
normal tissue complication probability; however, we suggest that they can be used as a 
valuable tool in comparing and evaluating different treatment techniques and protocols. 
 
Conclusions 
This study has investigated the use of radiobiological models that have recently become 
available in a commercial treatment planning system (Pinnacle v.7.6) to determine a more 
clinically meaningful evaluation of the different methods for delivering radiotherapy 
treatments to prostate patients. Tumour control probability (TCP) and normal tissue 
complication probability (NTCP) were evaluated and compared for two different 3D 
conformal treatment plans and an intensity modulated radiotherapy treatment plan. The IMRT 
plan was found to significantly reduce the NTCP for the rectum while achieving a small gain 
in TCP. The effect of different fractionation schedules for dose escalation was also 
investigated. The effect of these different fractionation schedules was found to be strongly 
dependent on the α/β of the prostate. If the α/β is indeed lower than previously assumed 
(around 1.5) then increasing the dose/fraction was shown to significantly improve the TCP for 
all four of the published hypo-fractionation schedules, 60 Gy (20 x 3 Gy), 70 Gy (28 x 2.5 
Gy), 50 Gy (16 x 3.125 Gy) and 55 Gy (20 x 2.75 Gy). If the α/β is closer to the previously 
assumed value (around 10.0) then improvements in TCP were observed for only the 60 Gy 
(20 x 3 Gy) and  70 Gy (28 x 2.5 Gy) hypo-fractionation schedules. This study showed that 
radiobiological parameters can be effectively used to determine a more clinically meaningful 
evaluation of a radiotherapy treatment plan than just dose and volume. The dependence of 
TCP on the α/β parameter for the prostate highlights the need for more clinical studies such as 
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the CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy 
for Prostate Cancer) trial
36
 and assessment of patient follow up data to validate and refine the 
use of these radiobiological models and the parameters used in them. This will be the first 
step in achieving the holy grail of radiotherapy, patient specific biologically optimised 
radiotherapy treatments. 
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Table 1 
 
Table 1. Parameters used in the radiobiological models for calculation of TCP and NTCP. 
The values listed here are part of a radiobiological database in the Pinnacle treatment planning 
system that is based on published data. 
 
Organ D50 γ α/β Relative seriality 
Prostate (PTV) 52.57 4.2 1-10 - 
Bladder 80 3 3.0 0.18 
Rectum 80 2.2 3.0 1.5 
Femoral heads 65 2.7 3.0 1.0 
 
 
 
 
Table 2 
 
Table 2. Dose prescriptions for treatment trials in 3D-CRT 4 field, 3D-CRT 5 field and IMRT 
plans. BED2 is the biologically equivalent 2 Gy per fraction dose for α/β=1.5 and α/β=10 
Dose 
(Gy) No. of fractions Fraction size (Gy) 
BED2 (α/β=1.5) (Gy) BED2 (α/β=10) (Gy) 
60 30 2.000 60.0 60.0 
61 30 2.033 61.6 61.1 
62 30 2.066 63.2 62.3 
63 30 2.100 64.8 63.5 
64 30 2.133 66.4 64.7 
65 30 2.166 68.1 65.6 
66 30 2.200 69.8 67.1 
67 30 2.233 71.5 68.3 
68 30 2.266 73.2 69.5 
70 30 2.333 76.6 71.9 
62 31 2.000 - - 
64 32 2.000 - - 
66 33 2.000 - - 
68 34 2.000 - - 
70 35 2.000 - - 
 
 
Table 3 
 
Table 3. Published prostate hypo-fractionation trials that were investigated in this study. The 
BED2 was calculated for α/β = 1.5 and α/β =10.0. 
 
Fractionation 
Schedule 
Biologically Equivalent 
2 Gy Dose [α/β =1.5] 
Biologically Equivalent 
2 Gy Dose [α/β =10.0] 
Trial Reference 
60 Gy (20 x 3 Gy) 77.1 Gy 65.0 PMH, Toronto
37
 
70 Gy (28 x 2.5 Gy) 80.0 Gy 72.9 Cleveland Clinic, OH
38
 
50 Gy (16 x 3.125 Gy) 66.1 Gy 54.7 Christie Hospital
39
 
55 Gy (20 x 2.75 Gy) 66.8 Gy 58.4 Adelaide Hospital
40
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Figure 1 
 
 
 
 
 
Figure 1. The contoured patient volumes used in this study, PTV, rectal wall, bladder wall 
and femoral heads.  
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Figure 2 
 
 
 
Figure 2. TCPs as a function of prescription dose planned (I) in 30 fractions (solid line) and 
(II) in 2 Gy per fraction (dotted line)  in 3D-CRT 4fields (diamond), 3D-CRT 5 fields 
(square), and IMRT (triangle) plans for α/β = 1, 1.5, 2, 2.5, 3, 4, 5, and 10 Gy. 
 
 21 
 
Figure 3 
 
 
 
Figure 3.  NTCPs for rectum, bladder, femur heads, and composite NTCPs as a function of 
prescription dose for a fixed 30 fractions and a variable dose/fraction (solid line) and also for 
a fixed 2 Gy per fraction but variable number of fractions (dotted line). Calculations for the 
three different treatment planning techniques are shown for comparison.   
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Figure 4 
 
 
Figure 4. Complication free tumour control probability (P+) as a function of prescription 
dose planned in (I) a fixed 30 fractions and (II) a fixed 2 Gy/fraction in different treatment 
plans forIα/β value = 1, 1.5, 2, 2.5, 3, 4, 5 and 10 Gy. 
 
 23 
 
Figure 5 
 
 
 
 
Figure 5. TCPs as a function of α/β value for the prescription dose of 62, 64, 66, 68 and 70 
Gy planned (I) in 30 fractions (solid line) and (II) in 2 Gy/fraction (dotted line)  in 3D-CRT 4 
field (diamond), 3D-CRT 5 field (square), and IMRT (triangle) plans. 
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Figure 6 
 
 
 
Figure 6. Plots of calculated (a) TCP and (b) P+ values for conventional and hypo-
fractionated IMRT as a function of the biologically equivalent 2 Gy dose. 
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Figure Captions: 
 
 
Figure 1. The contoured patient volumes used in this study, PTV, rectal wall, bladder wall 
and femoral heads.  
 
Figure 2. TCPs as a function of prescription dose planned (I) in 30 fractions (solid line) and 
(II) in 2 Gy per fraction (dotted line)  in 3D-CRT 4fields (diamond), 3D-CRT 5 fields 
(square), and IMRT (triangle) plans for α/β = 1, 1.5, 2, 2.5, 3, 4, 5, and 10 Gy. 
 
Figure 3.  NTCPs for rectum, bladder, femur heads, and composite NTCPs as a function of 
prescription dose for a fixed 30 fractions and a variable dose/fraction (solid line) and also for 
a fixed 2 Gy per fraction but variable number of fractions (dotted line). Calculations for the 
three different treatment planning techniques are shown for comparison.   
 
Figure 4. Complication free tumour control probability (P+) as a function of prescription 
dose planned in (I) a fixed 30 fractions and (II) a fixed 2 Gy/fraction in different treatment 
plans forIα/β value = 1, 1.5, 2, 2.5, 3, 4, 5 and 10 Gy. 
 
Figure 5. TCPs as a function of α/β value for the prescription dose of 62, 64, 66, 68 and 70 
Gy planned (I) in 30 fractions (solid line) and (II) in 2 Gy/fraction (dotted line)  in 3D-CRT 4 
field (diamond), 3D-CRT 5 field (square), and IMRT (triangle) plans. 
 
Figure 6 Plots of calculated (a) TCP and (b) P+ values for conventional fractionation and 
published hypo-fractionated IMRT schedules as a function of the biologically equivalent 2 Gy 
dose. 
 
 
 
 
